FDA Probes Intuitive Surgical on Complication Rates

Fri, 03/01/2013 - 11:11am
Mass Device

The FDA surveys doctors on complications experienced using Intuitive Surgical's da Vinci surgical robot, sending shares down on Wall Street.

Intuitive Surgical

The FDA is looking into complication rates for surgeries using Intuitive Surgical's (NSDQ:ISRG) da Vinci surgical robot, sending a survey to doctors who use the device.

New of the probe, first reported by Bloomberg, sent ISRG shares down 11.1% to $509.89 apiece on Wall Street yesterday. The stock recovered some of that today, hitting $547.62 in pre-market trading and reaching $552.47 each as of about 11 this morning.

The FDA asked surgeons at "key hospitals" to detail any complications they've seen with the da Vinci robot, according to a copy of the survey obtained by the news service. The survey also asked about procedures the device might be good for and those it might not be ideal for and about the training they received on using the device.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.